Many hospitals have abused the 340B program which was intended to help patients, but healthcare systems saw it as an opportunity to increase their revenue.
I invited Sayeh Nikpay, Ph.D., MPH of Vanderbilt University School of Medicine to explain the origins of 340B, how safety-net clinics, as well as large hospitals, became participants in the program, and the possibility of getting rid of the program altogether.
You want to listen to this one.
Dr Nabhan and the podcast guests have no relevant financial disclosures.
This podcast is produced by the Journal of Clinical Pathways.
Dr. Pedro Barata, Director of the Clinical Genitourinary Medical Oncology Research Program at UH Seidman Cancer Center, provides an exclusive round-up of the most groundbreaking and practice-changing research unveiled at the ASCO GU 2024 meeting. With expertise and insight, he delves into pivotal studies such as CheckMate 914 Part B and KEYNOTE-564, exploring their implications
Dr. LaBelle elucidates the complexities of sickle cell disease, unraveling the devastating impact it has on individuals. The episode delves into various treatments and approaches to combat this formidable disease, including bone marrow transplant and the groundbreaking use of CRISPR-Cas9 technology. LaBelle shares insights into the recent research breakthroughs, citing the remarkable research report published
n this poignant episode, USA Today investigative journalist Emily Le Coz unravels the heart-wrenching narrative of Ashleigh Anderson, a CVS pharmacist whose tragic demise serves as a cautionary tale of overwhelming stress in the workplace. Emily shares her motivations behind delving into the pervasive issue of burnout in retail pharmacy and sheds light on the
